Patent Application Titled "Multiparticulate Dosage Forms Comprising Deutetrabenazine" Published Online (USPTO 20240374528).

A patent application titled "Multiparticulate Dosage Forms Comprising Deutetrabenazine" has been published online, detailing controlled release oral dosage forms for the administration of deutetrabenazine. Deutetrabenazine is a VMAT2 inhibitor used in the treatment of chorea associated with Huntington's disease and tardive dyskinesia. The dosage forms aim to provide sustained and controlled release of the drug for improved dosing regimens, potentially allowing for once-daily administration. The inventors seek to address the need for alternative dosage forms that maintain the treatment effects of current medications. [Extracted from the article]